2. Search Result
Search Result
Results for "

intestinal secretion

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

12

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10000
    Peptide YY (PYY) (3-36), Human

    		Neuropeptide Y Receptor Metabolic Disease
    Peptide YY (PYY) (3-36), Human is an endogenous appetite suppressing peptide. Peptide YY (PYY) (3-36), Human, a neuropeptide Y (NPY) Y2 receptor agonist, is a powerful inhibitor of intestinal secretion .
    Peptide YY (PYY) (3-36), Human
  • HY-105017
    Evodenoson

    ATL 313; DE 112

    		 Adenosine Receptor Infection Inflammation/Immunology
    Evodenoson is a selective agonist of the A2A adenosine receptor. Evodenoson’s primary actions include reducing inflammatory responses, decreasing intestinal fluid secretion, edema, tissue damage, and neutrophil infiltration induced by Clostridium difficile toxin A. Evodenoson’s protective effect is achieved by reducing myeloperoxidase (MPO) and adenosine deaminase (ADA) activities, and by lowering the production of tumor necrosis factor-alpha (TNF-α) .
    Evodenoson
  • HY-P0055
    GLP-1(7-37)
    3 Publications Verification

    		 GCGR Metabolic Disease
    GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
    GLP-1(7-37)
  • HY-P0055A
    GLP-1(7-37) acetate
    3 Publications Verification

    		 GCGR Metabolic Disease
    GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .
    GLP-1(7-37) acetate
  • HY-108278
    Zolimidine

    		Others Endocrinology
    Zolimidine, a derivate of imidazopyridine, is an orally active antiulcer agent. Zolimidine stimulates mucus secretion in intestinal mucosal cells and enhacnes intestinal wall more resistant to ulceration. Zolimidine exhibits gastroprotective effect in duodenal ulcer research .
    Zolimidine
  • HY-P0054
    GLP-1(7-36), amide acetate
    Maximum Cited Publications
    7 Publications Verification

    Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate

    		 GCGR Metabolic Disease
    GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.
    GLP-1(7-36), amide acetate
  • HY-P0054B
    GLP-1(7-36), amide TFA
    Maximum Cited Publications
    7 Publications Verification

    Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA

    		 GCGR Metabolic Disease
    GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .
    GLP-1(7-36), amide TFA
  • HY-P0276
    GIP, human
    1 Publications Verification

    Gastric Inhibitory Peptide (GIP), human

    		 Insulin Receptor Metabolic Disease
    GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
    GIP, human
  • HY-P0276A
    GIP, human TFA
    1 Publications Verification

    Gastric Inhibitory Peptide (GIP), human TFA

    		 Insulin Receptor Metabolic Disease
    GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
    GIP, human TFA
  • HY-B0680
    Lubiprostone (hemiketal)

    RU-0211 (hemiketal); SPI-0211 (hemiketal)

    		 Chloride Channel Others Cancer
    Lubiprostone (hemiketal) (RU-0211 (hemiketal)) is a selective chloride channel 2 (CLCN2) activator. Lubiprostone (hemiketal) is used to treat chronic idiopathic constipation and opioid-induced constipation by activating CLCN2 channels to increase chloride ion secretion in the intestine, thereby increasing intestinal fluid secretion and enhancing intestinal peristalsis. Lubiprostone (hemiketal) can be used in the study of chronic constipation and cancer .
    Lubiprostone (hemiketal)
  • HY-123879
    BAA473

    		Interleukin Related Inflammation/Immunology
    BAA473 is a bile acid analog and is a potent activator of the pyrin inflammasome that induces the secretion of interleukin 18 (IL-18) through activation of the inflammasome in both myeloid and intestinal epithelial cells .
    BAA473
  • HY-113929
    Loperamide oxide

    R-58425

    		 Others Inflammation/Immunology
    Loperamide oxide (R-58425) is a orally active prodrug of the Loperamide (HY-156131). Loperamide oxide incubation with the contents of the intestinal lumen inhibits fluid secretion under aerobic conditions .
    Loperamide oxide
  • HY-W153897
    N-Methyltyramine

    		Adrenergic Receptor Metabolic Disease
    N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .
    N-Methyltyramine
  • HY-P0221C
    PACAP (1-38) free acid

    		PACAP Receptor Endocrinology
    PACAP (1-38) free acid is an endogenous neuropeptide. PACAP (1-38) free acid potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .
    PACAP (1-38) free acid
  • HY-W153897R
    N-Methyltyramine (Standard)

    		Adrenergic Receptor Metabolic Disease
    N-Methyltyramine (Standard) is the analytical standard of N-Methyltyramine. This product is intended for research and analytical applications. N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .
    N-Methyltyramine (Standard)
  • HY-P3954
    Somatostatin-28 (sheep, human rat mouse)

    		Somatostatin Receptor Metabolic Disease
    Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .
    Somatostatin-28 (sheep, human rat mouse)
  • HY-P0221B
    PACAP (1-38) free acid TFA

    		PACAP Receptor Endocrinology
    PACAP (1-38) free acid TFA is an endogenous neuropeptide. PACAP (1-38) free acid TFA potently stimulates antral motility and somatostatin secretion, inhibits the secretion of gastrin and stimulates the release of vasoactive intestinal polypeptide, gastrin releasing peptide and substance P. PACAP (1-38) free acid TFA also enhances N-methyl-D-aspartate receptor function and expression of brain-derived neurotrophic factor through RACK1 .
    PACAP (1-38) free acid TFA
  • HY-113929R
    Loperamide oxide (Standard)

    		Others Inflammation/Immunology
    Loperamide oxide (Standard) is the analytical standard of Loperamide oxide. This product is intended for research and analytical applications. Loperamide oxide (R-58425) is a orally active prodrug of the Loperamide (HY-156131). Loperamide oxide incubation with the contents of the intestinal lumen inhibits fluid secretion under aerobic conditions .
    Loperamide oxide (Standard)
  • HY-15790A
    Elobixibat hydrate

    A 3309 hydrate; AZD 7806 hydrate

    		 Apical Sodium-Dependent Bile Acid Transporter Metabolic Disease
    Elobixibat hydrate is a potent ileal bile acid transporter (IBAT) inhibitor, with IC50 values of 0.53 ± 0.17 nM, 0.13 ± 0.03 nM, and 5.8 ± 1.6 nM for human IBAT, mouse IBAT, and canine IBAT. Elobixibat hydrate can be used for chronic idiopathic constipation (CIC) research .
    Elobixibat hydrate
  • HY-P1072
    PHM-27 (human)

    		CGRP Receptor Cardiovascular Disease Metabolic Disease
    PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC50 of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .
    PHM-27 (human)
  • HY-161620
    DW18134

    		IRAK Inflammation/Immunology
    DW18134 is an inhibitor for interleukin receptor-associated kinase 4 (IRAK 4) with an IC50 of 11.2 nM. DW18134 inhibits phosphorylation of IRAK4 and IKK, downregulates the secretion of TNF-α and IL-6. DW18134 attenuates the Lipopolysaccharides (HY-D1056)-induced peritonitis and DSS-induced colitis in mouse models, and protects the intestinal barrier function .
    DW18134
  • HY-17623
    Tegoprazan
    2 Publications Verification

    CJ-12420; RQ-00000004

    		 Proton Pump Potassium Channel Na+/K+ ATPase Inflammation/Immunology
    Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H +/K +-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H +/K +-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan
  • HY-17623S
    Tegoprazan-d6

    CJ-12420-d6; RQ-00000004-d6

    		 Proton Pump Na+/K+ ATPase Metabolic Disease
    Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan-d6
  • HY-B1264
    Celiprolol hydrochloride
    1 Publications Verification

    		 NO Synthase Adrenergic Receptor Cardiovascular Disease
    Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure .
    Celiprolol hydrochloride
  • HY-119873
    Celiprolol

    REV 5320

    		 NO Synthase Adrenergic Receptor Cardiovascular Disease
    Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure .
    Celiprolol
  • HY-B1264R
    Celiprolol (hydrochloride) (Standard)

    		NO Synthase Adrenergic Receptor Cardiovascular Disease
    Celiprolol (hydrochloride) (Standard) is the analytical standard of Celiprolol (hydrochloride). This product is intended for research and analytical applications. Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure .
    Celiprolol (hydrochloride) (Standard)
  • HY-168168
    (5aS,6R,6aR)-MK-8666

    		Others Metabolic Disease
    (5aS,6R,6aR)-MK-8666 is a selective GPR40 agonist with activity in promoting fatty acid-induced insulin secretion in pancreatic β cells and intestinal enteroendocrine cells. (5aS,6R,6aR)-MK-8666 has been studied for the inhibition of type 2 diabetes and has shown significant blood glucose lowering effects. Although (5aS,6R,6aR)-MK-8666 is considered to have potential inhibitory advantages, its development was stopped in Phase I clinical trials due to liver safety issues .
    (5aS,6R,6aR)-MK-8666

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: